In contrast with the large number of compounds declared as NRF2 activators, very few compounds are recognized as NRF2 inhibitors; these ones have been mostly investigated as anticancer agents (direct or indirect, and in combinations), or as sensitizers of cancer cells to anticancer chemotherapeutics [33,67,102,103]. Here, NFE2L2 is linked to cancer.